TCM
ARRY

Timpani Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Timpani Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$4.57M Buy
+187,268
New +$3.9M 2.18% 10

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Timpani Capital Management's ARRY Position: Q1 2019 in Review

Timpani Capital Management opened a new position in Array Biopharma Inc (ARRY) in Q1 2019: 187,268 shares worth $4.57M. The stake represents 2.18% of the portfolio and ranks #10 among its holdings.

268 funds tracked by Wall St. Rank hold ARRY as of Q1 2019.

  • Timpani Capital Management held 187,268 shares of Array Biopharma Inc worth $4.57M as of Q1 2019.
  • Array Biopharma Inc was a new Timpani Capital Management position in Q1 2019.
  • Array Biopharma Inc made up 2.18% of Timpani Capital Management's portfolio in Q1 2019, its #10 holding.
  • 268 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q1 2019.

Based on Timpani Capital Management's 13F filing for Q1 2019, filed 10 May 2019.